Drugs / INO-1001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00272415 | Oct 2005 → ? | melanoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00271167 | Oct 2005 → Jun 2006 | heart disorder | Inotek Pharmaceuticals Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00271765 | Jan 2004 → Jun 2006 | acute myocardial infarction | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00272415 ↗ |
| Action | Inhibit | “an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor” NCT00271167 ↗ |
| Route | Intravenous | “an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor” NCT00271167 ↗ |